“`html
NEW YORK and PARSIPPANY,N.J., Jan. 11, 2026 – Royalty Pharma and Teva Pharmaceuticals announced a funding agreement today that could reach $500 million to speed up the advancement of a potential new treatment for autoimmune diseases. The deal centers around Teva’s experimental antibody, TEV-‘408, which is currently being studied for vitiligo and celiac disease.
A New Hope for Autoimmune Patients?
Table of Contents
The collaboration aims to accelerate the clinical development of TEV-‘408, offering potential new therapies for conditions with limited treatment options.
- Royalty Pharma will initially provide $75 million to co-fund a Phase 2b study for vitiligo.
- An additional $425 million could be provided to support Phase 3 development if Phase 2b results are promising.
- TEV-‘408 targets interleukin-15 (IL-15) to reduce immune-mediated damage in vitiligo and celiac disease.
- The drug is designed for prolonged half-life and convenient self-management.
- TEV-‘408 has received Fast Track designation from the U.S. Food and Drug Administration.
For individuals grappling with celiac disease, where gluten triggers an immune response in the small intestine, new treatment options are desperately needed. TEV-‘408, an investigational human monoclonal antibody, offers a glimmer of hope by targeting interleukin-15 (IL-15), a cytokine involved in these immune pathways.
What makes TEV-‘408 Different?
TEV-‘408 isn’t just another drug in development. It’s designed with a prolonged half-life and a convenient self-administration option, perhaps making it easier for patients to manage their condition. Currently, vitiligo treatment is largely limited to topical therapies effective on only small areas of the body, leaving a significant unmet need for systemic options.
What are the potential benefits of blocking IL-15 activity? By inhibiting IL-15, TEV-‘408 aims to reduce the immune-mediated destruction of melanocytes in vitiligo, restoring pigment, or lessen the intestinal inflammation and damage seen in celiac disease.
The Financial Details
Under the terms of the agreement, Royalty Pharma will provide up to $500 million to Teva. The initial $75 million will co-fund a Phase 2b study for vitiligo. If the Phase 2b results are promising, Royalty Pharma has the option to contribute an additional $425 million to support the Phase 3 development program. Upon approval and launch, Teva will pay Royalty pharma a milestone payment and ongoing royalties on worldwide net sales of TEV-‘408.
“We are delighted to enter into this second collaboration with Teva as they advance the development of TEV-‘408,” said Pablo Legorreta,Chief Executive Officer and chairman of the Board of Royalty pharma. “Vitiligo is a chronic autoimmune skin disease that can have a profound emotional and psychosocial burden, yet current treatment options are insufficient. Our continued collaboration underscores Royalty Pharma’s role as a long-term,trusted partner with a focus on funding innovation in potentially transformative and practice changing therapies.”
Richard Francis, President, and CEO of Teva, added, “Strategic collaborations fuel innovation. This agreement with Royalty Pharma enables us to advance our science more efficiently and accelerate our pipeline to deliver meaningful solutions for patients worldwide. Vitiligo represents a significant unmet need, with only one approved topical treatment currently available and no systemic options. We are dedicated to driving scientific progress that brings new, effective therapies to people living with chronic autoimmune diseases.”
Understanding Vitiligo and the Need for New Treatments
Vitiligo affects people of all ages, skin types, and ethnicities, with an estimated global prevalence of 0.5% to 2%, though many cases go undiagnosed. Beyond the visible white patches on the skin, vitiligo can considerably impact a person’s emotional and social well-being, leading to anxiety, depression, and isolation.
TEV-‘408 is currently in Phase 1b clinical trials (NCT06625177) for vitiligo and Phase 2a trials (NCT06807463) for celiac disease. The U.S.
